Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells 26,530 Shares of Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $362,480. This trade represents a 86.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Simrat Randhawa also recently made the following trade(s):

• On Thursday, March 12th, Simrat Randhawa sold 33,830 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $81.48, for a total value of $2,756,468.40.

Dianthus Therapeutics Stock Down 8.8%

Shares of Dianthus Therapeutics stock traded down $7.88 on Tuesday, reaching $81.57. 1,057,924 shares of the stock were exchanged, compared to its average volume of 877,083. Dianthus Therapeutics, Inc. has a twelve month low of $16.64 and a twelve month high of $96.50. The firm has a market capitalization of $4.46 billion, a price-to-earnings ratio of -19.75 and a beta of 1.18. The business has a 50 day moving average price of $86.99 and a two-hundred day moving average price of $62.62.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.22. The business had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. Research analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Analyst Ratings Changes

DNTH has been the subject of several recent research reports. William Blair reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a report on Monday, March 16th. Raymond James Financial raised shares of Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $63.00 to $123.00 in a report on Tuesday, March 10th. Stifel Nicolaus set a $120.00 target price on shares of Dianthus Therapeutics in a report on Monday, March 9th. Wells Fargo & Company initiated coverage on shares of Dianthus Therapeutics in a report on Thursday, March 19th. They set an “overweight” rating and a $135.00 target price for the company. Finally, Truist Financial lifted their target price on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $117.82.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in DNTH. Raymond James Financial Inc. acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $27,000. First Horizon Corp acquired a new position in shares of Dianthus Therapeutics during the 1st quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Dianthus Therapeutics during the 4th quarter worth approximately $40,000. Russell Investments Group Ltd. acquired a new position in shares of Dianthus Therapeutics during the 3rd quarter worth approximately $64,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after buying an additional 3,317 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.